UA116981C2 - Сполуки для лікування спінальної м'язової атрофії - Google Patents
Сполуки для лікування спінальної м'язової атрофіїInfo
- Publication number
- UA116981C2 UA116981C2 UAA201409921A UAA201409921A UA116981C2 UA 116981 C2 UA116981 C2 UA 116981C2 UA A201409921 A UAA201409921 A UA A201409921A UA A201409921 A UAA201409921 A UA A201409921A UA 116981 C2 UA116981 C2 UA 116981C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 title abstract 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 | |
| PCT/US2013/025292 WO2013119916A2 (en) | 2012-02-10 | 2013-02-08 | Compounds for treating spinal muscular atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116981C2 true UA116981C2 (uk) | 2018-06-11 |
Family
ID=48948163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201409921A UA116981C2 (uk) | 2012-02-10 | 2013-02-08 | Сполуки для лікування спінальної м'язової атрофії |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (OSRAM) |
| EP (2) | EP3406252B1 (OSRAM) |
| JP (2) | JP6092897B2 (OSRAM) |
| KR (2) | KR102341596B1 (OSRAM) |
| CN (3) | CN108299314B (OSRAM) |
| AR (1) | AR092794A1 (OSRAM) |
| AU (2) | AU2013216870B2 (OSRAM) |
| BR (1) | BR112014019750B1 (OSRAM) |
| CA (1) | CA2863874C (OSRAM) |
| CL (1) | CL2014002100A1 (OSRAM) |
| CO (1) | CO7061082A2 (OSRAM) |
| CR (1) | CR20140376A (OSRAM) |
| DK (1) | DK2812004T3 (OSRAM) |
| EA (2) | EA037123B1 (OSRAM) |
| EC (1) | ECSP14017269A (OSRAM) |
| ES (1) | ES2697174T3 (OSRAM) |
| HU (1) | HUE039779T2 (OSRAM) |
| IL (2) | IL233959A (OSRAM) |
| MA (1) | MA35920B1 (OSRAM) |
| MX (2) | MX354074B (OSRAM) |
| NZ (1) | NZ628186A (OSRAM) |
| PE (1) | PE20142364A1 (OSRAM) |
| PH (2) | PH12018501711B1 (OSRAM) |
| PL (1) | PL2812004T3 (OSRAM) |
| SG (2) | SG11201404713PA (OSRAM) |
| TR (1) | TR201813877T4 (OSRAM) |
| TW (2) | TWI585085B (OSRAM) |
| UA (1) | UA116981C2 (OSRAM) |
| WO (1) | WO2013119916A2 (OSRAM) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| USRE47689E1 (en) | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| EA037123B1 (ru) * | 2012-02-10 | 2021-02-09 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| BR112015015075A2 (pt) * | 2012-12-24 | 2019-01-15 | Univ Ramot | agentes para tratar doenças genéticas resultantes de mutações sem sentido e métodos para identificar as mesmas. |
| JP6689197B2 (ja) | 2013-08-19 | 2020-04-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | スクリーニング方法 |
| EP3082820B1 (en) * | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| RS59718B1 (sr) | 2014-05-15 | 2020-01-31 | Hoffmann La Roche | Jedinjenja za lečenje spinalne mišićne atrofije |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| CA2963288A1 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016066142A1 (en) * | 2014-11-01 | 2016-05-06 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| WO2016111896A1 (en) * | 2015-01-05 | 2016-07-14 | Sikorsky Aircraft Corporation | Integrated vibration damper for additively manufactured structure and method |
| EP3298017B1 (en) * | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| AR106652A1 (es) * | 2015-11-12 | 2018-02-07 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrófica |
| BR112018009281B1 (pt) | 2015-11-12 | 2023-10-31 | F. Hoffmann-La Roche Ag | Composições para tratar atrofia muscular espinhal e seu uso |
| RS60834B1 (sr) | 2015-12-09 | 2020-10-30 | Cadent Therapeutics Inc | Modulatori heteroaromatskog nmda receptora i njihove upotrebe |
| JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| MX382671B (es) | 2015-12-10 | 2025-03-13 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017186668A1 (en) | 2016-04-28 | 2017-11-02 | F. Hoffmann-La Roche Ag | A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one |
| EP3471779A4 (en) | 2016-06-16 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | COMBINATIONS FOR MODULATING SMN EXPRESSION |
| JP2019535789A (ja) * | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP3558318B1 (en) * | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2019015578A (es) * | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MY201938A (en) | 2017-08-04 | 2024-03-25 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| LT3673080T (lt) | 2017-08-25 | 2023-12-27 | Stoke Therapeutics, Inc. | Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti |
| MX2020002711A (es) | 2017-09-22 | 2020-07-20 | Hoffmann La Roche | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. |
| GB2584204B (en) | 2017-10-23 | 2023-06-28 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| LT3814357T (lt) | 2018-06-27 | 2024-06-25 | Ptc Therapeutics, Inc. | Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui |
| EA202092899A1 (ru) | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
| EP4223760B1 (en) | 2018-08-03 | 2025-06-04 | Novartis AG | Heteroaromatic nmda receptor modulator and uses thereof |
| CN112805009A (zh) * | 2018-08-07 | 2021-05-14 | 费城儿童医院 | 基因表达的选择性剪接调控及治疗方法 |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| EP4004003A1 (en) | 2019-07-31 | 2022-06-01 | Teva Pharmaceuticals International GmbH | Solid state forms of risdiplam and process for preparation thereof |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| JP7765088B2 (ja) | 2019-12-02 | 2025-11-06 | ストーム・セラピューティクス・リミテッド | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
| WO2021154842A1 (en) | 2020-01-28 | 2021-08-05 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| JP7728772B2 (ja) * | 2020-02-12 | 2025-08-25 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法 |
| JP2023515619A (ja) | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調節するための化合物及び方法 |
| MX2022010683A (es) | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| CA3169697A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| CA3173034A1 (en) | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating smn2 |
| JP2023515617A (ja) | 2020-02-28 | 2023-04-13 | リミックス セラピューティクス インコーポレイテッド | 核酸スプライシングを調節するためのピリダジン誘導体 |
| EP4132646A1 (en) | 2020-04-08 | 2023-02-15 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2021207550A1 (en) | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| EP4150092A4 (en) | 2020-05-11 | 2024-11-06 | Stoke Therapeutics, Inc. | OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS |
| JP2023532332A (ja) | 2020-07-02 | 2023-07-27 | リミックス セラピューティクス インコーポレイテッド | 核酸のスプライシング及び増殖性疾患の処置のためのモジュレーターとしての２－（インダゾール－５－イル）－６－（ピペリジン－４－イル）－１，７－ナフチリジン誘導体及び関連する化合物 |
| KR20230118067A (ko) | 2020-07-02 | 2023-08-10 | 레믹스 테라퓨틱스 인크. | 5-[5-(피페리딘-4-일)티에노[3,2-c]피라졸-2-일]인다졸 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물 |
| WO2022070071A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| CA3212341A1 (en) | 2021-03-17 | 2022-09-22 | F. Hoffmann-La Roche Ag | New thiazolopyrimidinone derivatives |
| TW202321206A (zh) | 2021-07-28 | 2023-06-01 | 美商普羅泰戈生物製藥股份有限公司 | 轉甲狀腺素蛋白穩定化合物 |
| MX2024002558A (es) | 2021-08-30 | 2024-04-30 | Remix Therapeutics Inc | Compuestos y métodos para modular splicing. |
| EP4396177A1 (en) | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250333397A1 (en) | 2021-08-30 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202328135A (zh) | 2021-08-30 | 2023-07-16 | 美商雷密克斯醫療公司 | 調節剪接之化合物及用途 |
| WO2023064879A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| TW202333689A (zh) | 2021-10-13 | 2023-09-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| TW202337442A (zh) | 2022-01-05 | 2023-10-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| US20250109140A1 (en) | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024251925A1 (en) * | 2023-06-09 | 2024-12-12 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| WO2025233837A1 (en) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) * | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| WO1993023398A1 (en) * | 1992-05-13 | 1993-11-25 | E.I. Du Pont De Nemours And Company | Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides |
| JPH11510478A (ja) * | 1995-06-06 | 1999-09-14 | アボツト・ラボラトリーズ | キノリジノン型化合物 |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| WO2000017197A1 (en) | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| AU7961100A (en) * | 1999-10-28 | 2001-05-08 | Daiichi Pharmaceutical Co., Ltd. | Drug discharge pump inhibitors |
| DE60128655T2 (de) * | 2000-01-24 | 2008-02-07 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| EP1389463A4 (en) | 2001-04-26 | 2008-09-17 | Daiichi Seiyaku Co | MEDICAMENT FOR INHIBITING A DRUG REMOVAL PUMP |
| EP2198867A1 (en) | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| CA2493458A1 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| MXPA05013142A (es) * | 2003-06-20 | 2006-03-17 | Chiron Corp | Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. |
| DE602005002562T2 (de) | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| CA2595477A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| WO2011062853A1 (en) * | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| JP2013517233A (ja) * | 2010-01-13 | 2013-05-16 | インスティチュート・パスツール・コリア | 抗感染ピリド（１，２−ａ）ピリミジン |
| USRE47689E1 (en) | 2011-12-30 | 2019-11-05 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| EA037123B1 (ru) * | 2012-02-10 | 2021-02-09 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| RS59718B1 (sr) | 2014-05-15 | 2020-01-31 | Hoffmann La Roche | Jedinjenja za lečenje spinalne mišićne atrofije |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/en active Active
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/en not_active Ceased
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/en active Active
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 CA CA2863874A patent/CA2863874C/en active Active
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786B1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116981C2 (uk) | Сполуки для лікування спінальної м'язової атрофії | |
| MX357834B (es) | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. | |
| MX352962B (es) | Compuestos para tratar atrofia muscular espinal. | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| PH12014502398A1 (en) | Pesticidal compositions and processes related thereto | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| WO2013120022A3 (en) | Treatment of hypoglycemia | |
| PH12015501393A1 (en) | Pesticidal compositions and processes related thereto | |
| JO3300B1 (ar) | مركبات وتركيبات لتعديل نشاط egfr | |
| WO2014052836A3 (en) | Methods and compositions for treating infection | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| GEP201706754B (en) | Proliposomal testosterone formulations | |
| MY157341A (en) | Methods and compositions for treating lung cancer | |
| AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
| PH12015501088A1 (en) | Dimeric compounds | |
| WO2012017321A3 (en) | Treatment for dyslipidemia | |
| MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. | |
| MX356102B (es) | Compuestos y métodos para tratar leucemia. | |
| GEP201706636B (en) | Galactagogue compositions based on phosphatidylserine | |
| GEP201706708B (en) | Isoxazolidine derivatives | |
| WO2013013238A3 (en) | Compounds and related compositions and methods of use | |
| WO2013013240A3 (en) | Macrocyclic compounds and related compositons and methods of use | |
| EP2544534A4 (en) | COMPOSITIONS, METHODS AND DEVICES USED IN THE TREATMENT OF DYSMENORRHEA | |
| IN2013CH00453A (OSRAM) | ||
| TN2014000207A1 (en) | Anti il-36r antibodies |